【佳學(xué)基因檢測(cè)】血清微衛(wèi)星分析檢測(cè)食管腺癌

靶向藥一個(gè)月費(fèi)用排序

閱讀腫瘤啟動(dòng)預(yù)防及反復(fù)抑制基因檢測(cè)，在消化科腫瘤正確治療專(zhuān)場(chǎng)聽(tīng)到《Eur J Surg Oncol》在. 2006 Nov;32(9):954-60.發(fā)表了一篇題目為《血清微衛(wèi)星分析檢測(cè)食管腺癌》腫瘤靶向藥物治療基因檢測(cè)臨床研究文章。該研究由C F Eisenberger , N H Stoecklein, S Jazra, S B Hosch, M Peiper, P Scheunemann, J Schulte Am Esch, W T Knoefel等完成。研究食管腺癌的早期預(yù)警、轉(zhuǎn)移及反復(fù)特征的基因檢測(cè)，是醫(yī)學(xué)技術(shù)先進(jìn)的大夫及醫(yī)院選用的腫瘤基檢測(cè)項(xiàng)目。

腫瘤靶向藥物測(cè)序基因檢測(cè)研究?jī)?nèi)容關(guān)鍵詞：

血清,微衛(wèi)星分析,基因檢測(cè),食管腺癌

腫瘤靶向治療基因檢測(cè)臨床應(yīng)用結(jié)果

食管腺癌腫瘤基因檢測(cè)研究的背景與目的：器官局限型食管癌在許多患者中早期可以治好，而更廣泛的病變預(yù)后較差。我們?cè)噲D通過(guò)使用一種新的分子方法開(kāi)發(fā)一種用于癌癥檢測(cè)和評(píng)估患者預(yù)后的非侵入性測(cè)試。食管腺癌腫瘤基因檢測(cè)研究的材料和方法：從 32 例腺癌患者中獲得匹配的正常、腫瘤和血清樣本。食管。提取 DNA 并使用 12 個(gè)標(biāo)記對(duì)樣品進(jìn)行微衛(wèi)星分析。來(lái)自 10 名健康個(gè)體的血清和正常樣本作為對(duì)照。結(jié)果：32 名惡性腫瘤患者中有 27 名（84.4%）被發(fā)現(xiàn)在其原發(fā)腫瘤中有一個(gè)或多個(gè)微衛(wèi)星 DNA 改變。通過(guò)微衛(wèi)星分析，32 名患者中有 26 名（81.3%）的血清發(fā)生了改變。有趣的是，所有沒(méi)有淋巴轉(zhuǎn)移和三種早期癌（pT1pN0）的患者的血清中都顯示出 LOH 改變，而來(lái)自正常對(duì)照受試者的所有血清 DNA 均為陰性。存活率與腫瘤中的 LOH 或血清中的 LOH 均無(wú)顯著相關(guān)性。食管腺癌腫瘤基因檢測(cè)研究的結(jié)論：這些數(shù)據(jù)表明，血清樣本中的微衛(wèi)星 DNA 分析可能為早期發(fā)現(xiàn)食管癌提供潛在的有價(jià)值的工具。循環(huán)腫瘤 DNA 的證據(jù)反映了這些腫瘤擴(kuò)散到遠(yuǎn)處部位的傾向。到目前為止，隨訪時(shí)間仍然太短，無(wú)法就這一發(fā)現(xiàn)的預(yù)后影響得出進(jìn)一步的結(jié)論。

腫瘤發(fā)生與反復(fù)轉(zhuǎn)移國(guó)際數(shù)據(jù)庫(kù)描述：

Background and aims: Organ-confined oesophageal cancer in an early stage can be cured in many patients, whereas more extensive lesions have a poor prognosis. We sought to develop a non-invasive test for cancer detection and evaluation of the prognosis of the patients by using a novel molecular approach.Material and methods: Matched normal-, tumour- and serum-samples were obtained from 32 patients with adenocarcinoma of the oesophagus. DNA was extracted and the samples were subjected to microsatellite analysis using 12 markers. Serum and normal samples from 10 healthy individuals served as controls.Results: Twenty-seven of the 32 patients (84.4%) with malignant tumours were found to have one or more microsatellite DNA alterations in their primary tumour. Twenty-six of the 32 patients (81.3%) had alterations in the serum by microsatellite analysis. Interestingly, all patients without lymphatic metastasis and three early carcinomas (pT1pN0) already displayed LOH alteration in the serum, while all serum DNA of samples from normal control subjects were negative. Survival was not significantly correlated with either LOH in the tumour or LOH in the serum.Conclusion: These data suggest that microsatellite DNA analysis in serum specimens might provide a potentially valuable tool for early detection of oesophageal cancer. The evidence of circulating tumour DNA reflects the propensity of these tumours to spread to distant sites. Up to now the follow-up is still too short to draw further conclusions on the prognostic impact of this finding.